There is evidence to back up the idea that some antidepressants can lower levels of various cytokines in both humans and animals, and more recently, it has been revealed that some antidepressant have antiviral effect against SARS-CoV-2. The purpose of this narrative review is to assess the potential value of antidepressants in the management of COVID-19 infection as well as the potential advantages and disadvantages of antidepressant therapy for COVID-19 infections and mental problems. An analysis of the recent literature was done to determine the place of antidepressant drugs in the care of COVID-19 patients. Additionally, two phase II studies investigating fluvoxamine that were published and showed promising results against a placebo for clinical deterioration and hospitalisation rate. The first stages of seven ongoing clinical trials are examining fluvoxamine, fluoxetine and tramadol. The results from several observational studies, two phase II clinical testing, and the aggregate of the antiviral and anti-inflammatory laboratory development form the basis for ongoing clinical trials trying to investigate the potential use of antidepressants for COVID-19 infection in humans, despite the amount of evidence is limited.
HTML PDFShare this article
Clinical Depression received 89 citations as per Google Scholar report
